Molecular biology of osteosarcoma

AM Czarnecka, K Synoradzki, W Firlej, E Bartnik… - Cancers, 2020 - mdpi.com
Osteosarcoma (OS) is the most frequent primary bone cancer in children and adolescents
and the third most frequent in adults. Many inherited germline mutations are responsible for …

Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy

F Cersosimo, S Lonardi, G Bernardini, B Telfer… - International journal of …, 2020 - mdpi.com
Osteosarcomas (OSs) are bone tumors most commonly found in pediatric and adolescent
patients characterized by high risk of metastatic progression and recurrence after therapy …

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

MM Gounder, NP Agaram, SE Trabucco… - Nature …, 2022 - nature.com
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA

M Yang, H Zheng, K Xu, Q Yuan, Y Aihaiti… - Frontiers in …, 2022 - frontiersin.org
Objective Osteosarcoma (OS) is a common bone malignancy with poor prognosis. We
aimed to investigate the relationship between cuproptosis-related lncRNAs (CRLncs) and …

Current status and prospects of targeted therapy for osteosarcoma

Z Hu, S Wen, Z Huo, Q Wang, J Zhao, Z Wang, Y Chen… - Cells, 2022 - mdpi.com
Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high
propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS …

Origin and therapies of osteosarcoma

B Moukengue, M Lallier, L Marchandet, M Baud'huin… - Cancers, 2022 - mdpi.com
Simple Summary Osteosarcoma is the most common malignant bone tumor in children, with
a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the …

MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression

J Lin, A Xu, J Jin, M Zhang, J Lou, C Qian, J Zhu… - …, 2022 - Taylor & Francis
The poor progress of immunotherapy on osteosarcoma patients requires deeper delineation
of immune tolerance mechanisms in the osteosarcoma microenvironment and a new …

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

HL Gardner, K Sivaprakasam, N Briones… - Communications …, 2019 - nature.com
Osteosarcoma (OS) is a rare, metastatic, human adolescent cancer that also occurs in pet
dogs. To define the genomic underpinnings of canine OS, we performed multi-platform …

Targeted therapy for osteosarcoma: a review

S Li, H Zhang, J Liu, G Shang - Journal of cancer research and clinical …, 2023 - Springer
Background Osteosarcoma is a common primary malignant tumour of the bone that usually
occurs in children and adolescents. It is characterised by difficult treatment, recurrence and …

Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis

M Homayoonfal, Z Asemi, B Yousefi - Cellular & Molecular Biology Letters, 2022 - Springer
Despite great advances, therapeutic approaches of osteosarcoma, the most prevalent class
of preliminary pediatric bone tumors, as well as bone-related malignancies, continue to …